Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Metformin
Bamlanivimab Molnupiravir
Bromhexine Nigella Sativa
Budesonide Nitazoxanide
Casirivimab/i.. Povidone-Iod..
Colchicine Probiotics
Conv. Plasma Proxalutamide
Curcumin Quercetin
Favipiravir Remdesivir
Fluvoxamine Sotrovimab
Hydroxychloro.. Vitamin A
Iota-carragee.. Vitamin C
Ivermectin Vitamin D
Melatonin Zinc

Other Adoption
 
00.250.50.7511.251.51.752+Fischer (RCT)77%0.23 [0.01-5.69]death0/1401/62Improvement, RR [CI]TreatmentControlMerck (RCT)94%0.06 [0.00-1.01]death0/3858/377Tau​2 = 0.00; I​2 = 0.0%Early treatment89%0.11 [0.01-0.90]0/5259/43989% improvementAll studies89%0.11 [0.01-0.90]0/5259/43989% improvement2 molnupiravir COVID-19 studiesc19mp.com Oct 16, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 2.05Effect extraction pre-specifiedFavors molnupiravirFavors control
Database of all molnupiravir COVID-19 studies. There is substantial positive publication bias. Three trials (NCT04575584 and trials by Aurobindo Pharma and MSN Laboratories) have reported no significant efficacy, however the results have not been published yet. Submit updates/corrections.
Oct 1
Early Merck News Release (News) death, ↓94.2%, p=0.003 Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
Details   News release reporting interim analysis of the MOVe-OUT trial, showing significantly lower risk of hospitalization or death. NCT04575597.
Jul 9
Animal Abdelnabi et al., The Journal of Infectious Diseases, doi:10.1093/infdis/jiab361 (Peer Reviewed) animal study Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model
Details   Hamster study showing molnupiravir effective against the original, B.1.1.7, and B.1.351 variants.
Jun 18
Early Fischer et al., medRxiv, doi:10.1101/2021.06.17.21258639 (Preprint) death, ↓76.5%, p=0.31 Molnupiravir, an Oral Antiviral Treatment for COVID-19
Details   RCT 202 outpatients in the USA showing significantly faster viral clearance, but no significant differences in symptom duration or severity. NCT04405570.
May 7
In Vitro Zhou et al., The Journal of Infectious Diseases, doi:10.1093/infdis/jiab247 (Peer Reviewed) (In Vitro) in vitro β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
Details   In Vitro study showing that NHC (initial metabolite of molnupiravir) has high antiviral activity against SARS-CoV-2, but also shows host mutational activity in an animal cell culture assay. Authors note the concern that mutations in host ..
Apr 15
Late Merck, News Release (Preprint) Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19
Details   News release reporting that the trial of molnupiravir with hospitalized patients (NCT04575584) has been discontinued because data indicates it is unlikely to demonstrate a clinical benefit in hospitalized patients. Results are not availab..
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit